RCT | Peanut patch therapy is effective in desensitizing young children with allergies, but raises risk of serious adverse events

Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary on Twitter

In the phase 3 EPITOPE trial involving children 1 to 3 years of age with peanut allergy, epicutaneous immunotherapy by means of a peanut patch was superior to placebo in desensitizing children to peanut. https://t.co/USk6HBI9Qh#pediatrics

— NEJM (@NEJM) May 10, 2023